TRANSDOMINANT INHIBITION OF WILD-TYPE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 REPLICATION BY AN ENVELOPE DELETION MUTANT

被引:22
作者
STEFFY, KR
WONGSTAAL, F
机构
[1] UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093
[2] UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093
关键词
D O I
10.1128/JVI.67.4.1854-1859.1993
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The envelope glycoprotein of human immunodeficiency virus type 2 (HIV-2) is primarily responsible for virus attachment and entry into the target cell population. We constructed an HIV-2 mutant virus containing an in-frame deletion within the putative CD4-binding sequences of the envelope glycoprotein and confirmed that the mutant envelope is unable to bind CD4 and that the mutant virus is noninfectious. To investigate whether this mutant could dominantly interfere with wild-type replication, we coexpressed proviral DNAs of both wild-type and mutant viruses in cells and assayed the production of infectious HIV-2 virions. Interference with virus replication was indeed observed with mutant DNA, and a maximal effect was achieved with 10-fold excess mutant DNA over wild-type DNA in the cotransfection experiments. The transdominant effect on virus replication does not appear to be at the level of wild-type envelope expression or gp120-CD4 interaction. Rather, the interference may be at the level of mixed-oligomer formation during progeny virus assembly and may occur by either destabilizing the multimeric structure of gp120 or forming a defective mixed multimeric gp120 which is unable to complete the receptor binding and/or postbinding events needed for infection.
引用
收藏
页码:1854 / 1859
页数:6
相关论文
共 31 条
[1]   SYNTHESIS, OLIGOMERIZATION, AND BIOLOGICAL-ACTIVITY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 ENVELOPE GLYCOPROTEIN EXPRESSED BY A RECOMBINANT VACCINIA VIRUS [J].
CHAKRABARTI, S ;
MIZUKAMI, T ;
FRANCHINI, G ;
MOSS, B .
VIROLOGY, 1990, 178 (01) :134-142
[2]   DEMONSTRATION OF 2 DISTINCT CYTOPATHIC EFFECTS WITH SYNCYTIUM FORMATION-DEFECTIVE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MUTANTS [J].
DEDERA, D ;
RATNER, L .
JOURNAL OF VIROLOGY, 1991, 65 (11) :6129-6136
[3]   OLIGOMERIC STRUCTURE OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN [J].
EARL, PL ;
DOMS, RW ;
MOSS, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (02) :648-652
[4]   LIPOFECTION - A HIGHLY EFFICIENT, LIPID-MEDIATED DNA-TRANSFECTION PROCEDURE [J].
FELGNER, PL ;
GADEK, TR ;
HOLM, M ;
ROMAN, R ;
CHAN, HW ;
WENZ, M ;
NORTHROP, JP ;
RINGOLD, GM ;
DANIELSEN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7413-7417
[5]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A REPLICATION COMPETENT HUMAN IMMUNODEFICIENCY TYPE-2 (HIV-2) PROVIRAL CLONE [J].
FRANCHINI, G ;
FARGNOLI, KA ;
GIOMBINI, F ;
JAGODZINSKI, L ;
DEROSSI, A ;
BOSCH, M ;
BIBERFELD, G ;
FENYO, EM ;
ALBERT, J ;
GALLO, RC ;
WONGSTAAL, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) :2433-2437
[6]   A MUTATION IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMEMBRANE GLYCOPROTEIN-GP41 DOMINANTLY INTERFERES WITH FUSION AND INFECTIVITY [J].
FREED, EO ;
DELWART, EL ;
BUCHSCHACHER, GL ;
PANGANIBAN, AT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (01) :70-74
[7]   THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 VPR GENE IS ESSENTIAL FOR PRODUCTIVE INFECTION OF HUMAN MACROPHAGES [J].
HATTORI, N ;
MICHAELS, F ;
FARGNOLI, K ;
MARCON, L ;
GALLO, RC ;
FRANCHINI, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (20) :8080-8084
[8]   FUNCTIONAL INACTIVATION OF GENES BY DOMINANT NEGATIVE MUTATIONS [J].
HERSKOWITZ, I .
NATURE, 1987, 329 (6136) :219-222
[9]   FUNCTIONAL REGIONS OF THE ENVELOPE GLYCOPROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
KOWALSKI, M ;
POTZ, J ;
BASIRIPOUR, L ;
DORFMAN, T ;
WEI, CG ;
TERWILLIGER, E ;
DAYTON, A ;
ROSEN, C ;
HASELTINE, W ;
SODROSKI, J .
SCIENCE, 1987, 237 (4820) :1351-1355
[10]  
KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367